Identification of differentially expressed genes associated with the pathogenesis of gastric cancer by bioinformatics analysis

AIM

Gastric cancer (GC) is one of the most diagnosed cancers worldwide. GC is a heterogeneous disease whose pathogenesis has not been entirely understood. Besides, the GC prognosis for patients remains poor. Hence, finding reliable biomarkers and therapeutic targets for GC patients is urgently needed.

METHODS

GSE54129 and GSE26942 datasets were downloaded from Gene Expression Omnibus (GEO) database to detect differentially expressed genes (DEGs). Then, gene set enrichment analyses and protein-protein interactions were investigated. Afterward, ten hub genes were identified from the constructed network of DEGs. Then, the expression of hub genes in GC was validated. Performing survival analysis, the prognostic value of each hub gene in GC samples was investigated. Finally, the databases were used to predict microRNAs that could regulate the hub genes. Eventually, top miRNAs with more interactions with the list of hub genes were introduced.

RESULTS

In total, 203 overlapping DEGs were identified between both datasets. The main enriched KEGG pathway was "Protein digestion and absorption." The most significant identified GO terms included "primary alcohol metabolic process," "basal part of cell," and "extracellular matrix structural constituent conferring tensile strength." Identified hub modules were COL1A1, COL1A2, TIMP1, SPP1, COL5A2, THBS2, COL4A1, MUC6, CXCL8, and BGN. The overexpression of seven hub genes was associated with overall survival. Moreover, among the list of selected miRNAs, hsa-miR-27a-3, hsa-miR-941, hsa-miR-129-2-3p, and hsa-miR-1-3p, were introduced as top miRNAs targeting more than five hub genes.

CONCLUSIONS

The present study identified ten genes associated with GC, which may help discover novel prognostic and diagnostic biomarkers as well as therapeutic targets for GC. Our results may advance the understanding of GC occurrence and progression.

Molecular evaluation of sheep and goats isolates of Pasteurella multocida and their antibiotic resistance

Pasteurella multocida exists as a commensal in the upper respiratory tracts of livestock, and poultry, and causes a wide variety of diseases in humans and animals. This study aimed to investigate the incidence of P. multocida by bacteriological and molecular characterization in sheep and goats and screening the existence of capsule-specific genes and their antibiotic resistance pattern. Totally, 1650 nasopharyngeal swabs were collected from apparently healthy sheep and goats and 460 lung tissues were collected from slaughtered animals in Fars province, Iran. All samples were cultured and suspected colonies were examined by biochemical tests, antimicrobial assay and polymerase chain reaction (PCR). Among 165 P. multocida (104 sheep and 61 goats) isolates, the capA, capD, and capB genes were amplified in 98, 48, and 12 isolates, respectively. The occurrence of four virulence-associated genes of P. multocida isolates were determined by PCR. Most isolates harbored the toxA (79.40%) and hgbB genes (70.90%) and 59.40% of isolates had the pfhA gene. Almost half of the isolates (46.10%) contained the tbpA gene. According to the current study, P. multocida capsular type A had the most frequency followed by type D. In addition, the high frequency of tbpA, pfhA, toxA, and hgbB genes revealed that these genes are possibly important in the pathogenesis of P. multocida. Oxytetracycline, enrofloxacin, florfenicol, and tilmicosin were the most effective drugs.

Effect of intradermal injection of heparinase III on skin wound healing in diabetic rats

AIM

neuropathy and vascular damage in this disease. Heparanase is an endoglycosidase that degrades heparan sulfate in the extracellular matrix and is believed to promote angiogenesis. The present study has been performed to investigate the effect of heparinase III (an enzyme which exclusively cleaves heparan sulfate) on wound healing in diabetic rats.

METHODS

The rats became diabetic by a single streptozotocin injection. Two weeks later, a wound was created by excision of the skin in the left paravertebral area. Heparinase III (0.2 unit) was injected intradermally around the wound every 5 days, starting on day one, for a total of three doses. The wound area was measured every 3 days. After completion of wound healing, full thickness skin samples were taken from the wound sites and evaluated for volume density of the collagen bundles, numerical density of the fibroblasts, and length density of the vessels.

RESULTS

Heparinase III accelerated wound closure compared to control diabetic animals. Microscopical examination revealed that it increased angiogenesis with no significant effect on collagen density and the number of fibroblasts.

CONCLUSION

Heparinase III induces angiogenesis and improves wound healing in diabetic animal model.